Cannabinoid modulation of fear extinction brain circuits: A novel target to advance anxiety treatment

Current Pharmaceutical Design

Volumn 20, Issue 13, 2014, Pages 2212-2217

  Rabinak, Christine A ^a   Phan, K Luan ^a,b,c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Amygdala; Anxiety; Cannabinoid; Cognitive enhancer; Fear extinction; Hippocampus; Ventromedial prefrontal cortex

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID; CANNABINOID 1 RECEPTOR; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NABILONE;

AMYGDALOID NUCLEUS; ANXIETY; ANXIETY DISORDER; BRAIN FUNCTION; FEAR; GENETIC VARIABILITY; HIPPOCAMPUS; HUMAN; LEARNING; MEMORY; NERVOUSNESS; NONHUMAN; PANIC; PHOBIA; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOTHERAPY; RECALL; REINFORCEMENT; REVIEW; TREATMENT OUTCOME; VENTROMEDIAL PREFRONTAL CORTEX; ANIMAL; ANXIETY DISORDERS; DRUG EFFECTS; PHYSIOLOGY;

ANIMALS; ANXIETY DISORDERS; CANNABINOIDS; EXTINCTION, PSYCHOLOGICAL; FEAR; HUMANS; RECEPTOR, CANNABINOID, CB1;

EID: 84903691607     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990437     Document Type: Review

References (101)

1. Rauch SL, Shin LM, Phelps EA. Neurocircuitry models of posttraumatic stress disorder and extinction: human neuroimaging research--past, present, and future. Biological Psychiatry 2006; 60: 376-82.
2. Rosen JB, Schulkin J. From normal fear to pathological anxiety. Psychol Rev 1998; 105: 325-50.
3. Norton PJ, Price EC. A meta-analytic review of adult cognitivebehavioral treatment outcome across the anxiety disorders. J Nerv Ment Dis 2007; 195: 521-31.
4. Hofmann SG. Cognitive processes during fear acquisition and extinction in animals and humans: implications for exposure therapy of anxiety disorders. Clinical Psychology Review 2008; 28: 199-210.
5. Bouton ME, Garcia-Gutierrez A, Zilski J, Moody EW. Extinction in multiple contexts does not necessarily make extinction less vulnerable to relapse. Behav Res Ther 2006; 44: 983-94.
6. Hermans D, Craske MG, Mineka S, Lovibond PF. Extinction in human fear conditioning. Biol Psychiatry 2006; 60: 361-8.
7. LaBar KS, Phelps EA. Reinstatement of conditioned fear in humans is context dependent and impaired in amnesia. Behav Neurosci 2005; 119: 677-86.
8. Milad MR, Orr SP, Pitman RK, Rauch SL. Context modulation of memory for fear extinction in humans. Psychophysiology 2005; 42: 456-64.
9. Myers KM, Davis M. Mechanisms of fear extinction. Mol Psychiatry 2007; 12: 120-50.
10. Vansteenwegen D, Hermans D, Vervliet B, et al. Return of fear in a human differential conditioning paradigm caused by a return to the original acquistion context. Behav Res Ther 2005; 43: 323-36.
11. Bouton ME. Context, ambiguity, and unlearning: sources of relapse after behavioral extinction. Biol Psychiatry 2002; 52: 976-86.
12. Jovanovic T, Ressler KJ. How the neurocircuitry and genetics of fear inhibition may inform our understanding of PTSD. Am J Psychiatry 2010; 167: 648-62.
13. Graham BM, Milad MR. The study of fear extinction: implications for anxiety disorders. American Journal of Psychiatry 2011; 168: 1255-65.
14. Milad MR, Quirk GJ. Fear extinction as a model for translational neuroscience: ten years of progress. Annu Rev Psychol 2012; 63: 129-51.
15. Bouton ME, Westbrook RF, Corcoran KA, Maren S. Contextual and temporal modulation of extinction: behavioral and biological mechanisms. Biol Psychiatry 2006; 60: 352-60.
16. Milad MR, Rauch SL, Pitman RK, Quirk GJ. Fear extinction in rats: implications for human brain imaging and anxiety disorders. Biological Psychology 2006; 73: 61-71.
17. Quirk GJ, Beer JS. Prefrontal involvement in the regulation of emotion: convergence of rat and human studies. Current Opinion in Neurobiology 2006; 16: 723-7.
18. Davis M, Whalen PJ. The amygdala: vigilance and emotion. Mol Psychiatry 2001; 6: 13-34.
19. LeDoux JE. Emotion circuits in the brain. Ann Rev Neurosci 2000; 23: 155-84.
20. Amano T, Unal CT, Pare D. Synaptic correlates of fear extinction in the amygdala. Nat Neurosci; 13: 489-94.
21. Pape HC, Pare D. Plastic synaptic networks of the amygdala for the acquisition, expression, and extinction of conditioned fear. Physiol Rev 2010; 90: 419-63.
22. Herry C, Ciocchi S, Senn V, Demmou L, Muller C, Luthi A. Switching on and off fear by distinct neuronal circuits. Nature 2008; 454: 600-6.
23. Phelps EA, Delgado MR, Nearing KI, LeDoux JE. Extinction learning in humans: role of the amygdala and vmPFC. Neuron 2004; 43: 897-905.
24. Milad MR, Quirk GJ. Neurons in medial prefrontal cortex signal memory for fear extinction. Nature 2002; 420: 70-4.
25. Pare D, Quirk GJ, Ledoux JE. New vistas on amygdala networks in conditioned fear. J Neurophysiol 2004; 92: 1-9.
26. Quirk GJ, Garcia R, Gonzalez-Lima F. Prefrontal mechanisms in extinction of conditioned fear. Biol Psychiatry 2006; 60: 337-43.
27. Quirk GJ, Likhtik E, Pelletier JG, Pare D. Stimulation of medial prefrontal cortex decreases the responsiveness of central amygdala output neurons. J Neurosci 2003; 23: 8800-7.
28. Quirk GJ, Mueller D. Neural mechanisms of extinction learning and retrieval. Neuropsychopharmacology 2008; 33: 56-72.
29. Ochsner KN, Gross JJ. The cognitive control of emotion. Trends Cogn Sci 2005; 9: 242-9.
30. Milad MR, Wright CI, Orr SP, Pitman RK, Quirk GJ, Rauch SL. Recall of fear extinction in humans activates the ventromedial prefrontal cortex and hippocampus in concert. Biological Psychiatry 2007; 62: 446-54.
31. Kalisch R, Korenfeld E, Stephan KE, Weiskopf N, Seymour B, Dolan RJ. Context-dependent human extinction memory is mediated by a ventromedial prefrontal and hippocampal network. Journal of Neuroscience 2006; 26: 9503-11.
32. Corcoran KA, Desmond TJ, Frey KA, Maren S. Hippocampal inactivation disrupts the acquisition and contextual encoding of fear extinction. J Neurosci 2005; 25: 8978-87.
33. LaBar KS, Gatenby JC, Gore JC, LeDoux JE, Phelps EA. Human amygdala activation during conditioned fear acquisition and extinction: a mixed-trial fMRI study. Neuron 1998; 20: 937-45.
34. Phelps EA, O'Connor KJ, Gatenby JC, Gore JC, Grillon C, Davis M. Activation of the left amygdala to a cognitive representation of fear. Nature Neuroscience 2001; 4: 437-41.
35. Milad MR, Quinn BT, Pitman RK, Orr SP, Fischl B, Rauch SL. Thickness of ventromedial prefrontal cortex in humans is correlated with extinction memory. Proc Natl Acad Sci USA 2005; 102: 10706-11.
36. Hartley CA, Fischl B, Phelps EA. Brain structure correlates of individual differences in the acquisition and inhibition of conditioned fear. Cereb Cortex 2011; 21: 1954-62.
37. Milad MR, Pitman RK, Ellis CB, et al. Neurobiological basis of failure to recall extinction memory in posttraumatic stress disorder. Biological Psychiatry 2009; 66: 1075-82.
38. van Minnen A, Hagenaars M. Fear activation and habituation patterns as early process predictors of response to prolonged exposure treatment in PTSD. J Traumatic Stress 2002; 15: 359-67.
39. Foa EB. Psychosocial treatment of posttraumatic stress disorder. Journal of Clinical Psychiatry 2000; 61 Suppl 5: 43-8; discussion 49-51.
40. Charney DS, Deutch A. A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. Critical Rev Neurobiol 1996; 10: 419-46.
41. Pitman RK, Shin LM, Rauch SL. Investigating the pathogenesis of posttraumatic stress disorder with neuroimaging. J Clin Psychiatry 2001; 62 Suppl 17: 47-54.
42. Orr SP, Metzger LJ, Lasko NB, Macklin ML, Peri T, Pitman RK. De novo conditioning in trauma-exposed individuals with and without posttraumatic stress disorder. Journal of Abnormal Psychology 2000; 109: 290-8.
43. Kaplan GB, Moore KA. The use of cognitive enhancers in animal models of fear extinction. Pharmacol Biochem Behav 2011; 99: 217-28.
44. Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418: 530-4.
45. de Oliveira Alvares L, Pasqualini Genro B, Diehl F, Molina VA, Quillfeldt JA. Opposite action of hippocampal CB1 receptors in memory reconsolidation and extinction. Neuroscience 2008; 154: 1648-55.
46. Lin HC, Mao SC, Su CL, Gean PW. The role of prefrontal cortex CB1 receptors in the modulation of fear memory. Cereb Cortex 2009; 19: 165-75.
47. Chhatwal JP, Davis M, Maguschak KA, Ressler KJ. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 2005; 30: 516-24.
48. Suzuki A, Josselyn SA, Frankland PW, Masushige S, Silva AJ, Kida S. Memory reconsolidation and extinction have distinct temporal and biochemical signatures. J Neurosci 2004; 24: 4787-95.
49. Pamplona FA, Bitencourt RM, Takahashi RN. Short-and longterm effects of cannabinoids on the extinction of contextual fear memory in rats. Neurobiol Learn Mem 2008; 90: 290-3.
50. Pamplona FA, Prediger RD, Pandolfo P, Takahashi RN. The cannabinoid receptor agonist WIN 55,212-2 facilitates the extinction of contextual fear memory and spatial memory in rats. Psychopharmacology (Berl) 2006; 188: 641-9.
51. Bitencourt RM, Pamplona FA, Takahashi RN. Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. European Neuropsychopharmacology 2008; 18: 849-59.
52. Varvel SA, Wise LE, Niyuhire F, Cravatt BF, Lichtman AH. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology 2007; 32: 1032-41.
53. Lin HC, Mao SC, Chen PS, Gean PW. Chronic cannabinoid administration in vivo compromises extinction of fear memory. Learn Mem 2008; 15: 876-84.
54. Lin HC, Mao SC, Gean PW. Effects of intra-amygdala infusion of CB1 receptor agonists on the reconsolidation of fear-potentiated startle. Learn Mem 2006; 13: 316-21.
55. D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004; 29: 1558-72.
56. Sethi BB, Trivedi JK, Kumar P, Gulati A, Agarwal AK, Sethi N. Antianxiety effect of cannabis: involvement of central benzodiazepine receptors. Biol Psychiatry 1986; 21: 3-10.
57. Wachtel SR, ElSohly MA, Ross SA, Ambre J, de Wit H. Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. Psychopharmacology (Berl) 2002; 161: 331-9.
58. Fabre LF, McLendon D. The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. Journal of Clinical Pharmacology 1981; 21: 377S-382S.
59. Gaetani S, Cuomo V, Piomelli D. Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends Mol Med 2003; 9: 474-8.
60. Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 2005; 81: 331-42.
61. Phan KL, Angstadt M, Golden J, Onyewuenyi I, Popovska A, de Wit H. Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J Neurosci 2008; 28: 2313-9.
62. Cornelius JR, Aizenstein HJ, Hariri AR. Amygdala reactivity is inversely related to level of cannabis use in individuals with comorbid cannabis dependence and major depression. Addict Behav 2010; 35: 644-6.
63. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010; 35: 764-74.
64. Fusar-Poli P, Crippa JA, Bhattacharyya S, et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 2009; 66: 95-105.
65. Viveros MP, Llorente R, Moreno E, Marco EM. Behavioural and neuroendocrine effects of cannabinoids in critical developmental periods. Behav Pharmacol 2005; 16: 353-62.
66. Genn RF, Tucci S, Marco EM, Viveros MP, File SE. Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test. Pharmacol Biochem Behav 2004; 77: 567-73.
67. Crippa JA, Zuardi AW, Garrido GE, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 2004; 29: 417-26.
68. Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 1993; 7: 82-8.
69. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimaraes FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006; 39: 421-9.
70. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982; 76: 245-50.
71. Fusar-Poli P, Allen P, Bhattacharyya S, et al. Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 2010; 13: 421-32.
72. Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 2011; 25: 121-30.
73. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 2011; 36: 1219-26.
74. Stern CA, Gazarini L, Takahashi RN, Guimaraes FS, Bertoglio LJ. On disruption of fear memory by reconsolidation blockade: evidence from cannabidiol treatment. Neuropsychopharmacology 2012; 37: 2132-42.
75. Bhattacharyya S, Atakan Z, Martin-Santos R, et al. Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of [delta]-9-tetrahydrocannabinol on midbrain and striatal function. Mol Psychiatry 2012; 17: 1152-5.
76. Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM. Gene-environment interplay between cannabis and psychosis. Schizophr Bull 2008; 34: 1111-21.
77. Henquet C, Rosa A, Krabbendam L, et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 2006; 31: 2748-57.
78. van Winkel R. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry 2011; 68: 148-57.
79. Hariri AR, Gorka A, Hyde LW, et al. Divergent effects of genetic variation in endocannabinoid signaling on human threat-and reward-related brain function. Biological Psychiatry 2009; 66: 9-16.
80. Gunduz-Cinar O, Macpherson KP, Cinar R, et al. Convergent translational evidence of a role for anandamide in amygdalamediated fear extinction, threat processing and stress-reactivity. Molecular Psychiatry 2012.
81. Klumpers F, Denys D, Kenemans JL, Grillon C, van der Aart J, Baas JM. Testing the effects of Delta9-THC and D-cycloserine on extinction of conditioned fear in humans. J Psychopharmacol 2012; 26: 471-8.
82. Rabinak CA, Angstadt M, Sripada CS, et al. Cannabinoid facilitation of fear extinction memory recall in humans. Neuropharmacology 2013; 64: 396-402.
83. Kirk JM, de Wit H. Responses to oral delta9-tetrahydrocannabinol in frequent and infrequent marijuana users. Pharmacol Biochem Behav 1999; 63: 137-42.
84. Milad MR, Zeidan MA, Contero A, et al. The influence of gonadal hormones on conditioned fear extinction in healthy humans. Neuroscience 2010; 168: 652-8.
85. Zeidan MA, Igoe SA, Linnman C, et al. Estradiol modulates medial prefrontal cortex and amygdala activity during fear extinction in women and female rats. Biological Psychiatry 2011; 70: 920-7.
86. Katona I, Rancz EA, Acsady L, et al. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. Journal of Neuroscience 2001; 21: 9506-18.
87. Katona I, Sperlagh B, Magloczky Z, et al. GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 2000; 100: 797-804.
88. Katona I, Sperlagh B, Sik A, et al. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 1999; 19: 4544-58.
89. Rabinak CA, Sripada CS, Angstadt M, de Wit H, Phan KL. Cannabinoid modulation of subgenual anterior cingulate cortex activation during experience of negative affect. J Neural Transm 2012; 119: 701-7.
90. Chhatwal JP, Ressler KJ. Modulation of fear and anxiety by the endogenous cannabinoid system. CNS Spectr 2007; 12: 211-20.
91. Lafenetre P, Chaouloff F, Marsicano G. The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction. Pharmacol Res 2007; 56: 367-81.
92. Campolongo P, Roozendaal B, Trezza V, et al. Endocannabinoids in the rat basolateral amygdala enhance memory consolidation and enable glucocorticoid modulation of memory. Proc Natl Acad Sci USA 2009; 106: 4888-93.
93. Rabinak CA, Angstadt M, Sripada CS, Milad MR, Phan KL. Cannabinoid modulation of fear extinction learning and underlying brain circuitry in healthy humans. In: ed. eds., Poster session presented at the annual meeting of the Society of Biological Psychiatry 67th Annual Scientific Convention & Program: Philadelphia, PA, May 2012.
94. Foa EB, Dancu CV, Hembree EA, Jaycox LH, Meadows EA, Street GP. A comparison of exposure therapy, stress inoculation training, and their combination for reducing posttraumatic stress disorder in female assault victims. J Consult Clin Psychol 1999; 67: 194-200.
95. Rothbaum BO, Astin MC, Marsteller F. Prolonged Exposure versus Eye Movement Desensitization and Reprocessing (EMDR) for PTSD rape victims. J Trauma Stress 2005; 18: 607-16.
96. Hembree EA, Foa EB, Dorfan NM, Street GP, Kowalski J, Tu X. Do patients drop out prematurely from exposure therapy for PTSD? J Trauma Stress 2003; 16: 555-62.
97. Stein DJ, Ipser J, McAnda N. Pharmacotherapy of posttraumatic stress disorder: a review of meta-analyses and treatment guidelines. CNS Spectr 2009; 14: 25-31.
98. Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev 2006: CD002795.
99. (IOM) IoM. Treatment of Posttraumatic Stress Disorder: An Assessment of the Evidence. The National Academies Press: Washington D.C. 2007.
100. Lutz B. The endocannabinoid system and extinction learning. Mol Neurobiol 2007; 36: 92-101.
101. Roche M, O'Connor E, Diskin C, Finn DP. The effect of CB(1) receptor antagonism in the right basolateral amygdala on conditioned fear and associated analgesia in rats. Eur J Neurosci 2007; 26: 2643-53.